medi-cal glp 1 coverage Health advocates are raising concerns after the state removed for certain obesity medications, including newer GLP-1 therapies often prescribed to help patients reduce weight and lower the risk of related The GLP-1 Access Gap: Mapping

This can increase intestinal permeability temporarily, which contributes to bloating, cramping, and the general digestive unease users report

Key drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound) are widely adopted due to their robust clinical outcomes and expanding global approvals

in the latter, proopiomelanocortin (POMC) neurons are present and it is believed that endogenous GLP-1 induces satiety, affecting both anorexigenic and orexigenic signaling pathways

To view or add a comment, sign in More Relevant Posts Kailera Therapeutics and Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals) Report Up to 12.1% Weight Loss in #Phase #2 #Obesity #Pill Study Kailera Therapeutics and its China partner Hengrui Pharma released topline Phase 2 data for oral ribupatide, showing up to 12.1% mean weight loss at 26 weeks a meaningful signal in the highly competitive oral obesity race

For the injectable GLP-1 RAs, this shouldnt be much of an issue, as the companys dosing aligns nicely with the research